XTL Biopharmaceuticals Ltd: Notice of AGM
26 September 2006 - 5:32PM
PR Newswire (US)
Annual General Meeting ("AGM") Notice Posted to Shareholders NEW
YORK, September 26 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals
Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL), a biotechnology company
focused on the acquisition, development and commercialization of
pharmaceutical products for the treatment of infectious diseases,
particularly the treatment of hepatitis C, has posted to
shareholders a notice convening its AGM. The AGM will take place at
the Conference Room at the Company's Israeli offices at Building 3,
Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m.,
on October 25, 2006. At the AGM it is proposed that: - the annual
reports for the year ended 31 December 2005 be received; -
Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed
as the Company's auditors; and - Messrs Michael Weiss, Ben Zion
Weiner and William Kennedy be re-appointed as Directors of the
Company. Contacts: XTL Ron Bentsur, Chief Executive Officer Tel:
+1-(212)-531-5960 ABOUT XTL BIOPHARMACEUTICALS LTD. XTL is engaged
in the acquisition, development and commercialization of
therapeutics for the treatment of infectious diseases, with a focus
on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase -
presently in Phase 1 clinical trials in patients with chronic
hepatitis C. XTL is also developing XTL-6865 - a combination of two
monoclonal antibodies against the hepatitis C virus - presently in
Phase 1 clinical trials in patients with chronic hepatitis C. XTL's
hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecules. XTL is publicly traded on the Nasdaq,
London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contacts: XTL, Ron Bentsur, Chief
Executive Officer Tel: +1-(212)-531-5960
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024